Kenvue (KVUE) FY2024 10-K Annual Report

Filed: Feb 24, 2025
Health Care
Perfumes, Cosmetics & Other Toilet PreparationsSEC EDGAR

Kenvue (KVUE) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 24, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.

Kenvue FY2024 10-K Analysis

Management Discussion & Analysis

  • Operating cash flow $1.8B down $1.4B YoY from $3.2B in fiscal 2023, decline driven by working capital changes
  • Financing cash outflow $1.6B in fiscal 2024, included $1.55B dividends and $235M share repurchases; repurchased 10.86M shares for $235M
+3 more insights

Risk Factors

  • Talc-related litigation risk for Johnson’s® Baby Powder sold outside US/Canada, with talc-based powder discontinued globally in 2023
  • Global operations exposed to foreign currency fluctuations and geopolitical conflicts impacting supply and costs
+3 more insights

Kenvue FY2024 Key Financial Metrics
XBRL

Revenue

$15.5B

+0.1% YoY

Net Income

$1.0B

-38.1% YoY

Gross Margin

58.0%

+200bp YoY

Operating Margin

11.9%

-435bp YoY

Net Margin

6.7%

-411bp YoY

ROE

10.7%

-419bp YoY

Total Assets

$25.6B

-8.1% YoY

EPS (Diluted)

$0.54

-40.0% YoY

Operating Cash Flow

$1.8B

-44.2% YoY

Source: XBRL data from Kenvue FY2024 10-K filing on SEC EDGAR. All figures in USD.

Other Kenvue Annual Reports

Get deeper insights on Kenvue

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.